These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 39229520)

  • 1. CircRAPGEF5 acts as a modulator of RAS/RAF/MEK/ERK signaling during colorectal carcinogenesis.
    Yin Z; Li H; Zhao H; Bentum-Ennin L; Xia Y; Wang Z; Hu W; Gu H; Zhang S; Li G
    Heliyon; 2024 Aug; 10(16):e36133. PubMed ID: 39229520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationships among
    Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
    World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation.
    Heard JJ; Phung I; Potes MI; Tamanoi F
    BMC Cancer; 2018 Jan; 18(1):69. PubMed ID: 29320991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation.
    Xu J; Pfarr N; Endris V; Mai EK; Md Hanafiah NH; Lehners N; Penzel R; Weichert W; Ho AD; Schirmacher P; Goldschmidt H; Andrulis M; Raab MS
    Oncogenesis; 2017 May; 6(5):e337. PubMed ID: 28504689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MEK inhibitors and DA-Raf, a dominant-negative antagonist of the Ras-ERK pathway, prevent the migration and invasion of KRAS-mutant cancer cells.
    Matsuda A; Masuzawa R; Takahashi K; Takano K; Endo T
    Cytoskeleton (Hoboken); 2024 Jun; ():. PubMed ID: 38872577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
    Joseph EW; Pratilas CA; Poulikakos PI; Tadi M; Wang W; Taylor BS; Halilovic E; Persaud Y; Xing F; Viale A; Tsai J; Chapman PB; Bollag G; Solit DB; Rosen N
    Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14903-8. PubMed ID: 20668238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathway crosstalk between Ras/Raf and PI3K in promotion of M-CSF-induced MEK/ERK-mediated osteoclast survival.
    Bradley EW; Ruan MM; Vrable A; Oursler MJ
    J Cell Biochem; 2008 Jul; 104(4):1439-51. PubMed ID: 18275061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HOXA3 promotes tumor growth of human colon cancer through activating EGFR/Ras/Raf/MEK/ERK signaling pathway.
    Zhang X; Liu G; Ding L; Jiang T; Shao S; Gao Y; Lu Y
    J Cell Biochem; 2018 Mar; 119(3):2864-2874. PubMed ID: 29073728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation.
    Avery TY; Köhler N; Zeiser R; Brummer T; Ruess DA
    Front Oncol; 2022; 12():931774. PubMed ID: 35965494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Chappell WH; Abrams SL; Wong EW; Chang F; Lehmann B; Terrian DM; Milella M; Tafuri A; Stivala F; Libra M; Basecke J; Evangelisti C; Martelli AM; Franklin RA
    Biochim Biophys Acta; 2007 Aug; 1773(8):1263-84. PubMed ID: 17126425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway.
    Andreadi C; Cheung LK; Giblett S; Patel B; Jin H; Mercer K; Kamata T; Lee P; Williams A; McMahon M; Marais R; Pritchard C
    Genes Dev; 2012 Sep; 26(17):1945-58. PubMed ID: 22892241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unraveling the interplay between RAS/RAF/MEK/ERK signaling pathway and autophagy in cancer: From molecular mechanisms to targeted therapy.
    Huang Y; Zhen Y; Chen Y; Sui S; Zhang L
    Biochem Pharmacol; 2023 Nov; 217():115842. PubMed ID: 37802240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: Current status in clinical trials.
    Song Y; Bi Z; Liu Y; Qin F; Wei Y; Wei X
    Genes Dis; 2023 Jan; 10(1):76-88. PubMed ID: 37013062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells.
    Oh YT; Deng J; Yue P; Sun SY
    Sci Rep; 2016 May; 6():26803. PubMed ID: 27222248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells.
    Suzuki R; Kikuchi S; Harada T; Mimura N; Minami J; Ohguchi H; Yoshida Y; Sagawa M; Gorgun G; Cirstea D; Cottini F; Jakubikova J; Tai YT; Chauhan D; Richardson PG; Munshi N; Ando K; Utsugi T; Hideshima T; Anderson KC
    PLoS One; 2015; 10(12):e0143847. PubMed ID: 26630652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PDCD6 cooperates with C-Raf to facilitate colorectal cancer progression via Raf/MEK/ERK activation.
    Wang X; Wu F; Wang H; Duan X; Huang R; Tuersuntuoheti A; Su L; Yan S; Zhao Y; Lu Y; Li K; Yao J; Luo Z; Guo L; Liu J; Chen X; Lu Y; Hu H; Li X; Bao M; Bi X; Du B; Miao S; Cai J; Wang L; Zhou H; Ying J; Song W; Zhao H
    J Exp Clin Cancer Res; 2020 Aug; 39(1):147. PubMed ID: 32746883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vertical Inhibition of the RAF-MEK-ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in
    Garcia N; Del Pozo V; Yohe ME; Goodwin CM; Shackleford TJ; Wang L; Baxi K; Chen Y; Rogojina AT; Zimmerman SM; Peer CJ; Figg WD; Ignatius MS; Wood KC; Houghton PJ; Vaseva AV
    Mol Cancer Ther; 2022 Jan; 21(1):170-183. PubMed ID: 34737198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
    Lamba S; Russo M; Sun C; Lazzari L; Cancelliere C; Grernrum W; Lieftink C; Bernards R; Di Nicolantonio F; Bardelli A
    Cell Rep; 2014 Sep; 8(5):1475-83. PubMed ID: 25199829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53-armed oncolytic adenovirus induces autophagy and apoptosis in KRAS and BRAF-mutant colorectal cancer cells.
    Tamura S; Tazawa H; Hori N; Li Y; Yamada M; Kikuchi S; Kuroda S; Urata Y; Kagawa S; Fujiwara T
    PLoS One; 2023; 18(11):e0294491. PubMed ID: 37972012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.